Physician profile
Ian Singer
NPI 1689237919
$1,646.62
in general payments reported to CMS, 2019-2025
17 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.13 · 2023: $660 · 2024: $811 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $350.05 | 2022-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $297.20 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Heartflow, INC. | $224.86 | 2023-2025 | Ffrct |
| Davol INC. | $161.86 | 2024 | Phasix Mesh |
| Intuitive Surgical, INC. | $109.93 | 2024 | |
| Lilly USA, LLC | $99.82 | 2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $79.36 | 2023 | |
| Abbott Laboratories | $65.35 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biosense Webster, INC. | $59.33 | 2023 | Carto 3 |
| Boston Scientific Corporation | $53.16 | 2023 | |
| Novartis Pharmaceuticals Corporation | $32.48 | 2023-2024 | |
| Shield Therapeutics INC | $25.08 | 2024 | |
| Phathom Pharmaceuticals, INC. | $25.00 | 2025 | Voquezna |
| Astellas Pharma US INC | $18.64 | 2024 | Veozah |
| Vivus LLC | $17.20 | 2024 | Pancreaze |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $14.56 | 2023 | |
| Glaxosmithkline, LLC. | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.